Spots Global Cancer Trial Database for Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Official Title: Activity and Enhancement of Immune Checkpoint Inhibition With Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC)
Study ID: NCT04610658
Study Description
Brief Summary: This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung cancer after progression with first-line, platinum-based chemotherapy
Detailed Description: Study was originally designed as a Phase I/II but was terminated during the Phase I portion due to dose limiting toxicities.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Advent Health - Celebration, Kissimmee, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Contact Details
Name: Alberto A Chiappori, MD
Affiliation: Moffitt Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
